What to Expect at the 3rd ADC Linker & Conjugation Summit
With all eyes on novel linker designs and new conjugation chemistry to move beyond the traditional, this year’s ADC Linker & Conjugation Summit returns to spotlight innovations that can elevate ADC performance to a whole new level.
Offering a technical program dedicated to experts in chemistry, bioconjugation, and protein engineering, this is the only ADC meeting that takes a deep dive into these critical details and goes beyond the literature.

Unmissable Agenda Highlights:
Enhancing Conjugation Chemistry for Dual-Payload ADCs
Unlocking the synergistic potential of dual-payload ADCs by exploring branched linker designs and advancing innovative conjugation chemistry with Sutro Biopharma, Catena Biosciences, and Araris Bio.
Next-Generation Conjugation Strategies
Moving away from maleimide chemistry - exploring the potential of next-generation conjugation strategies and site-specific technologies with Skymab Therapeutics, AstraZeneca, and Pfizer.
Advancing Linker Design Strategies
Achieving optimal stability profiles by showcasing new linker structures and discussing how to balance stability with controlled cleavage with NextPoint Therapeutics, Oncusp Therapeutics, and Glykos.
Innovative Linker & Conjugation Strategies
Overcoming novel payload challenges by utilizing solubility enhancers and tailored linker designs with Tubulis and Heidelberg Pharma
Deep Dive Sessions on Conjugation Site & DAR Stability
Join focused sessions to identify the optimal conjugation site and optimize the DAR/stability balance with Exelixis, ADC Therapeutics, and Glykos.
New Speaking Companies for 2025:








